Sunpeaks Ventures, Inc. (OTC:SNPK) and its fully owned subsidiary Healthcare Distribution Specialists, LLC (HDS) are delighted to declare that HDS has inked a Letter of Intent with PharmaLife® for placement of Clotamin® with leading pharmacies in the Russian Federation.
The Letter of Intent summarizes the terms and conditions of a proposed deal that could see Clotamin distributed by more than a few pharmacy and retail chains in the Russian Federation, counting product placement with leading wholesalers Imperia-Pharma, the Dr. Stoletov pharmacy chain (414 locations), and other little retail pharmacies linked with Imperia-Pharma. PharmaLife is as well anticipated to secure timely product registration within the Russian Federation for Clotamin distribution and conduct local market research to support a successful product release.
Its shares added 22.12% to close at $1.38 with the total traded volume of 27.28 million shares having the average volume of 26.56 million.
Its shares were trading within the range of $1.17-$1.40 while its opening price was $1.18. Its market capitalization is $475.17 million. Its stock price 52 weeks low was $0.28 and 52 weeks high price was $1.40.
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC (“HDS”), is a nationally focused, value-added distributor of specialty drugs and over-the-counter (“OTC”) branded multivitamins to the healthcare provider market.
HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions. For additional information, please visit www.sunpeaksventures.com.
The assembled information distributed by epicstocknews.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Epicstocknews.com does expect that investors will buy and sell securities based on information assembled and presented herein. Epicstocknews.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information.